Skip to main content

Table 1 Comparisons of multiple factors between RP-ILD and non-RP-ILD groups

From: The lungs were on fire: a pilot study of 18F-FDG PET/CT in idiopathic-inflammatory-myopathy-related interstitial lung disease

Factors RP-ILD (21) Non-RP-ILD (40) P value P-adjusted
Age(y) 54.86 ± 11.72 57.70 ± 11.06 0.354 0.824
Sex (male/female) 8/13 17/23 0.740 1.000
Course of disease(m) 2.00 (1.00, 2.75) 2.25 (1.00, 5.00) 0.253 0.748
Duration of diagnosis delay(m) 1.50 (0.50, 2.00) 1.00 (1.00, 3.00) 0.274 0.756
Clinical manifestations or complications  
Pulmonary bacterial infection 7 (33.3%) 4 (10.0%) 0.036 0.347
Pulmonary fungal infection 5 (23.8%) 4 (10.0%) 0.253 0.748
Tuberculosis infection 0 (0.0%) 0 (0.0%) NA NA
EBV infection 6 (28.6%) 5 (12.5%) 0.164 0.605
CMV infection 2 (9.5%) 0 (0.0%) 0.115 0.559
Carcinoma 1 (4.8%) 6 (15.0%) 0.405 0.824
Gastrointestinal haemorrhage 4 (19.0%) 1 (2.5%) 0.044 0.347
UIP pattern 3 (14.3%) 4 (10.0%) 0.683 0.962
Pneumomediastinum 1 (4.8%) 1 (2.5%) 1.000 1.000
Laboratory finding
Ferritin (ng/ml) 612.50 (302.05, 2110.25) 664.05 (314.40, 2061.23) 0.495 0.863
ESR (mm/h) 16.00 (6.50, 32.00) 17.50 (9.50, 42.00) 0.466 0.857
CRP (mg/L) 5.40 (3.10, 19.80) 6.35 (3.00, 36.73) 0.660 0.962
ALT(U/L) 37.00 (22.50, 99.50) 91.50 (33.75, 212.50) 0.051 0.347
AST(U/L) 45.00 (33.00, 97.00) 54.50 (34.00, 235.50) 0.224 0.725
LDH(U/L) 329.00 (275.50, 478.50) 323.00 (247.75, 461.50) 0.897 1.000
CK(U/L) 84.00 (50.50, 255.00) 86.00 (44.25, 415.25) 0.838 1.000
Disease activity  
MYOACT score 13.00 (9.00, 15.50) 9.00 (7.00, 10.75) 0.006 0.102
Lung function testing  
FVC% (%) 65.33 ± 20.08 71.86 ± 15.61 0.165 0.605
FEV1% (%) 64.85 ± 19.40 74.42 ± 18.25 0.062 0.383
FEV1/FVC 0.81 (0.75, 0.85) 0.81 (0.77,0.85) 0.849 1.000
TLC(L) 3.43 ± 1.01 3.98 ± 1.02 0.049 0.347
DLCO% (%) 50.29 ± 15.58 66.92 ± 16.67 < 0.001 0.014
18F-FDG PET/CT scan findings
Time gap after RS onset*(d) 20.00 (12.50, 25.00) 16.50 (13.00, 24.75) 0.767 1.000
Bilateral lung SUVmean 0.60 ± 0.15 0.45 ± 0.14 < 0.001 0.014
Abnormal mediastinal lymph node 14 (66.7%) 10 (25.0%) 0.002 0.045
Abnormal hilar lymph node 11 (52.4%) 9 (22.5%) 0.018 0.204
Liver SUVmean 1.83 ± 0.34 1.73 ± 0.47 0.412 0.824
Spleen SUVmean 2.02 ± 0.50 1.82 ± 0.46 0.126 0.571
Bone marrow SUVmean 1.72 ± 0.50 1.62 ± 0.44 0.402 0.824
Cardiac SUVmean 1.38 (1.00, 2.03) 1.60 (1.12, 2.39) 0.379 0.824
Oesophagus SUVmean 1.51 (1.19, 1.83) 1.34 (1.07, 1.74) 0.213 0.724
Stomach SUVmean 0.69 (0.49, 1.00) 0.71 (0.57, 0.83) 0.927 1.000
Small intestine SUVmean 1.05 ± 0.33 1.03 ± 0.32 0.878 1.000
Colon and rectum SUVmean 1.07 (0.80, 1.32) 1.02 (0.83, 1.20) 0.693 0.962
Bilateral cerebellum SUVmean 5.17 ± 1.26 5.24 ± 1.61 0.863 1.000
Bilateral trapezius SUVmean 0.82 (0.70, 0.96) 0.79 (0.68, 1.00) 0.585 0.944
Bilateral deltoid SUVmean 0.71 (0.58, 1.27) 0.78 (0.61, 1.09) 0.590 0.944
Bilateral biceps SUVmean 0.75 (0.67, 1.01) 0.77 (0.60, 1.10) 0.879 1.000
Bilateral iliopsoas SUVmean 1.10 ± 0.36 1.12 ± 0.36 0.850 1.000
Bilateral gluteus maximus SUVmean 0.85 ± 0.27 0.79 ± 0.32 0.462 0.857
Bilateral gluteus medius SUVmean 0.92 ± 0.29 0.98 ± 0.29 0.473 0.857
Bilateral quadriceps SUVmean 0.78 (0.62, 0.96) 0.82 (0.69, 1.05) 0.370 0.824
Myositis-specific antibodies and myositis-associated antibodies  
Anti-MDA5 13 (61.9%) 12 (30.0%) 0.016 0.204
Anti-PL-7 4 (19.0%) 2 (5.0%) 0.169 0.605
Anti-PL-12 1 (4.8%) 1 (2.5%) 1.000 1.000
Anti-EJ 0 (0.0%) 1 (2.5%) 1.000 1.000
Anti-OJ 0 (0.0%) 1 (2.5%) 1.000 1.000
Anti-Jo-1 2 (9.5%) 3 (7.5%) 1.000 1.000
Anti-TIF1γ 1 (4.8%) 3 (7.5%) 1.000 1.000
Anti-Mi-2α 0 (0.0%) 2 (5.0%) 0.541 0.920
Anti-Mi-2β 0 (0.0%) 4 (10.0%) 0.289 0.756
Anti-SAE1 0 (0.0%) 5 (12.5%) 0.154 0.605
Anti-NXP2 1 (4.8%) 6 (15.0%) 0.405 0.824
Anti-SRP 1 (4.8%) 2 (5.0%) 1.000 1.000
Anti-Ku 1 (4.8%) 1 (2.5%) 1.000 1.000
Anti-PM-Scl75 1 (4.8%) 2 (5.0%) 1.000 1.000
Anti-PM-Scl100 0 (0.0%) 0 (0.0%) NA NA
Anti-Ro-52 14 (66.7%) 17 (42.5%) 0.073 0.414
Therapies  
Steroid monotherapy 6 (28.6%) 14 (35.0%) 0.611 0.944
Steroid + DMARDs 7 (33.3%) 19 (47.5%) 0.288 0.756
Steroid+IVIG 2 (9.5%) 2 (5.0%) 0.602 0.944
Steroid+DMARDs+IVIG 3 (14.3%) 4 (10.0%) 0.683 0.962
Steroid + JAK inhibitor 3 (14.3%) 1 (2.5%) 0.113 0.559
IIM subtypes  
DM 13 (61.9%) 27 (67.5%) 0.662 0.962
PM 2 (9.5%) 7 (17.5%) 0.479 0.857
ADM 6 (28.6%) 6 (15.0%) 0.309 0.778
  1. RP-ILD, rapidly progressive interstitial lung disease; P-adjusted, adjusted P value after false discovery rate correction; y, years; m, months; NA, not available; EBV, Epstein-Barr virus; CMV, cytomegalovirus; UIP pattern, usual interstitial pneumonia pattern; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; ALT, alanine transaminase; AST, aspartate transaminase; LDH, lactate dehydrogenase; CK, creatine kinase; MYOACT, Myositis Disease Activity Assessment Visual Analogue Scales; FVC%, percent-predicted forced vital capacity; FEV1%, percent-predicted forced expiratory volume in 1 s; FEV1/FVC, ratio of FEV1 over FVC; TLC, total lung capacity; DLCO%, percent-predicted diffusing capacity of the lung for carbon monoxide; RS, respiratory symptoms; d, days; FDG, fluorodeoxyglucose; SUVmean, mean standard uptake value; DMARDs, disease-modifying anti-rheumatic drugs; IVIG, intravenous immunoglobulin; JAK, Janus kinase; IIM, idiopathic inflammatory myopathy; DM, dermatomyositis; PM, polymyositis; ADM, amyopathic dermatomyositis
  2. *Time gap after RS onset referred to the time gap between onset of respiratory symptoms (evident feelings of chest distress and shortness of breath) and PET/CT scan